Nasal Expiratory Positive Airway Pressure for the Treatment of Pediatric Obstructive Sleep Apnea Syndrome
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects age 5-16 years (note: Due to the size of the devices, it is expected that most children will be at least 8 years old, but a few may be younger. Subjects will be evaluated in clinic to fit for size and habituate to the device)
- OSAS (AHI > 5/hr)
- Subject has had adenotonsillectomy or is not a candidate for adenotonsillectomy
- Subject is non-adherent to CPAP or is seeking an alternative therapy
- Tolerance of NEPAP device during a daytime session
- Parental/guardian permission (informed consent) and if appropriate, child assent.
Exclusion Criteria:
- Severe developmental delay thought to involve a high risk of aspiration
- Family does not understand English well enough to perform the standardized, validated questionnaires.
- Age >16 years since results may be similar to adult studies in these older patients.
- Severe breathing disorder (including respiratory muscle weakness, bullous lung disease, bypassed upper airway, pneumothorax, pneumomediastinum)
- Severe heart disease (including heart failure)
- An acute upper respiratory (including nasal, sinus or middle ear) inflammation or infection or perforation of the ear drum
Subjects that do not meet all of the enrollment criteria will not be enrolled. Any violations of these criteria will be reported in accordance with Institutional Review Board (IRB) Policies and Procedures.
Study members will not recruit females who are known to be pregnant. However, if a subject becomes pregnant during the study, we will continue to use the device. Pregnancy is not an exclusion criterion as positive airway pressure therapy does not harm the pregnant woman or fetus.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Nasal Expiratory Positive Airway Pressure Devices
Nasal Expiratory Positive Airway Pressure Device
|
assigned to Nasal Expiratory Positive Airway Pressure arm
|
|
Sham Comparator: placebo sham
A sham device
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Apnea hypopnea index
Time Frame: Approximately one week
|
The apnea hypopnea index during polysomnography will be compared between the active device and the placebo nights
|
Approximately one week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adherence using daily logs
Time Frame: One month
|
Adherence with using devices will be determined by daily logs and collecting used devices
|
One month
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of life
Time Frame: One Month
|
The Pediatric Quality of Life (PedsQL) score will be compared at baseline and after one month of device usage
|
One Month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Carole Marcus, Children's Hospital of Philadelphia
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 12-008691
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Organic Pediatric Obstructive Sleep Apnea
-
NCT05052216RecruitingPediatric Obstructive Sleep Apnea
-
NCT03074747UnknownChiari Malformation | Questionnaire | Organic Obstructive Sleep Apnea (Diagnosis)
-
NCT06850220RecruitingCognition | Empathy | EEG | Pediatric Obstructive Sleep Apnea
-
NCT06917768CompletedPediatric Obstructive Sleep Apnea
-
NCT01276860CompletedPediatric Obstructive Sleep Apnea
-
NCT01680939UnknownPediatric Obstructive Sleep Apnea Syndrome
-
NCT03821831TerminatedPediatric Obesity | Pediatric Obstructive Sleep Apnea
-
NCT04321083UnknownObstructive Sleep Apnea | Pediatric Sleep Apnea
-
NCT00854334CompletedChildhood Obesity | Childhood Obstructive Sleep Apnea
Clinical Trials on Nasal Expiratory Positive Airway Pressure Device
-
NCT01872663CompletedRespiratory Tract Diseases | Pulmonary Atelectasis | Pathological Conditions, Signs and Symptoms
-
NCT04013360CompletedComplication, Postoperative | Cardiac Complication
-
NCT00188968CompletedApnea | Bronchopulmonary Dysplasia | Infant, Premature
-
NCT04742114RecruitingEmphysema | Bullous Disease Lung
-
NCT01318824Unknown
-
NCT03551314Completed
-
NCT01643421CompletedEffect of a Program of Deep Inspiration Combined to Expiratory Positive Airway Pressure in AsthmaticImprovement of Functional Capacity. | Improvement of Quality of Life. | Improvement of Cardiovascular Autonomic Control.